Seaport Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
(a) Recent Sales of Unregistered Equity Securities
None.
(b) Use of Proceeds from our Initial Public Offering
On April 30, 2026, the SEC declared effective our registration statement on Form S-1 (File No. 333-294976), as amended, or the
Registration Statement, filed in connection with our IPO. Pursuant to the Registration Statement, we registered the offer and sale of
14,160,000 shares of our common stock with a maximum aggregate offering price of approximately $237.0 million. Goldman Sachs &
Co. LLC, J.P. Morgan, Leerink Partners, Citigroup, and Stifel acted as representatives of the underwriters for the IPO. None of the
expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to
our affiliates.
There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus filed
with the SEC pursuant to Rule 424(b) of the Securities Act on May 1, 2026.
(c) Issuer Repurchases of Securities
None.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.